Gel-inducible composition for pet administration assistance

ABSTRACT

Provided is a gel-inducible composition for pet administration assistance. The gel-inducible composition for pet administration assistance has a viscosity sufficient to adhere to the ceiling of the pet&#39;s mouth by containing an oil component alone or containing a high concentration of a viscosity-adjusting agent in the oil component. When a powdered prescription drug is mixed with the composition, there is no layer separation between the composition and the powdered drug occurs, and when the mixture is scooped up with a finger and applied to the ceiling of the pet&#39;s mouth, the mixture completely adheres to the ceiling of the pet&#39;s mouth and the drug is naturally absorbed when the composition component melts. Thus, the composition makes it possible to administer the prescription drug at an appropriate dosage.

BACKGROUND 1. Technical Field

The present invention relates to a gel-inducible composition for petadministration assistance, and more particularly to a gel-induciblecomposition for pet administration assistance, which has a viscositysufficient to adhere to the ceiling of the pet's mouth by containing anoil component alone or containing a high concentration of aviscosity-adjusting agent in the oil component, and which is configuredsuch that, when a prescription drug is mixed with the composition andthe mixture is scooped up with a finger and applied to the ceiling ofthe pet's mouth, the mixture completely adheres to the ceiling of thepet's mouth without flowing down and the drug is naturally absorbed whenthe composition component melts.

2. RELATED ART

In modern society, pets are companion animals that live with people andare represented by dogs and cats. Pets are kept in close relationshipwith people and grow up while receiving more attention and care thananimals from people.

Therefore, when pets that are companion animals are sick due toabnormalities in health, these pets undergo a medical examination inveterinary hospitals and are administered by drugs. However, these drugsare mostly in the form of powders or pills and are administered throughthe oral cavity. At this time, pets with an excellent sense of smellfrequently refuse to take the drugs due to the smell of the drugs, andthus it is inconvenient to administer the drugs through the oral cavity,and the dosage is not reached. For these reasons, improvements arerequired.

As part of this effort, an oral liquid drug administration container forpets (Patent Document 1) was designed, which can more easily feed petswith liquid drugs or nutrients. It is a method of forcibly administeringa liquefied drug, obtained by powdering a drug and mixing the powderwith water, to the pet's oral cavity through a spoon for drugadministration or a syringe. However, pets are unable to swallowproperly due to the smell and bitter taste of the drug administeredthrough the oral cavity and spit out the administered drug again, makingit actually difficult to treat the pets with the drug. In particular, aproblem arises in that, if a dog or a cat experiences the bitterness ofa drug when administering the drug by a syringe, the animal does notcome to the guardian even if the guardian merely holds the syringe forsecond or later administration.

In another attempt, a drug-receiving space is formed in a pet feed, sothat a drug in a solid, capsule or powder form can be received in thefeed and the pet can take the drug received in the feed when eating thefeed, whereby the pet take the drug without aversion (Patent Document2). Alternatively, a method of administering a drug as a mixture withjam or honey is used. However, in this case, another problem arises inthat the jam or honey is harmful to the body because the sugar contentthereof is excessively high.

In addition, a frozen capsule formulation containing a drug in a hollowspace was proposed, which can be administered orally to a pet (PatentDocument 3).

However, it is still difficult to solve the problem that a pet refusesto take a prescription drug when administering the drug to the pet, andthus it is difficult to administer an appropriate dosage of the drug.

Accordingly, the present inventor has made efforts to solve the problemswith the conventional art, and as a result, has provided a gel-induciblecomposition for pet administration assistance, which has a viscositysufficient to adhere to the ceiling of the pet's mouth by containing anoil component alone or adjusting the viscosity by adding a highconcentration of a viscosity-adjusting agent to the oil component, andhas found that, when a prescription drug is added to and mixed with thecomposition and the mixture is scooped up with a finger and applied tothe ceiling of the pet's mouth, the mixture completely adheres to theceiling of the pet's mouth without flowing down and the drug isnaturally absorbed when the composition component melts, therebycompleting the present invention.

PRIOR ART DOCUMENTS Patent Documents

-   (Patent Document 1) Korean Utility Model Publication No. 0329124    (Sep. 26, 2003)-   (Patent Document 2) Korean Utility Model Application Laid-Open No.    2017-0000112 (Jan. 9, 2017)-   (Patent Document 3) US Patent Application Publication No.    2012-0321703 (Dec. 20, 2012).

SUMMARY OF THE INVENTION

An object of the present invention is to provide a gel-induciblecomposition for pet administration assistance.

Another object of the present invention is to provide a packaged gelinducible product for pet administration assistance in which a powderedprescription drug is contained in the gel-inducible composition for petadministration assistance.

To achieve the above objects, the present invention provides agel-inducible composition for pet administration assistance containingan oil component or containing a silicone-based or a biogum-basedviscosity-adjusting agent in the oil component.

The gel-inducible composition for pet administration assistanceaccording to the present invention may further contain an enzyme withthe oil component.

The enzyme contained may preferably be any one or more selected from thegroup consisting of protease, alpha-amylase, cellulase that is an enzymedegrading the dietary fiber cellulose, lipase, and pectinase that is anenzyme degrading the polysaccharide pectin.

The above-described gel-inducible composition for pet administrationassistance may have a viscosity of 9,500 to 100,000 cP as measured usinga rotational viscometer at a rotating speed of 10 rpm at a temperatureof 25° C.

The oil component of the present invention includes a vegetable oil oran animal oil. The vegetable oil is any one selected from the groupconsisting of canola oil, soybean oil, corn oil, grapeseed oil, and ricebran oil.

In addition, the silicone-based viscosity-adjusting agent is preferablysodium silicoaluminate, and the biogum-based viscosity-adjusting agentis any one selected from the group consisting of xanthan gum,carrageenan, guar gum, diutan gum, cellulose gum, and gellan gum.

The present invention also provides a packaged gel inducible product forpet administration assistance in which a powdered prescription drug iscontained in the gel-inducible composition for pet administrationassistance in an amount of 5 to 10 wt % based on the standard daily foodintake per body weight of a pet.

The packaged gel inducible product is characterized in that it is poorlysoluble in an aqueous phase and is soluble in an oil phase.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a photograph showing a packaged gel inducible product in whicha powdered drug is added to a gel-inducible composition for petadministration assistance according to the present invention.

FIG. 2 depicts photographs showing the dissolution behavior of a mixtureof a gel-inducible composition for pet administration assistanceaccording to the present invention and a powdered drug in an aqueousphase.

FIG. 3 shows in vivo pharmacokinetics (AUC results) of enrofloxacin withtime after administration of a mixture of a gel-inducible compositionfor pet administration assistance according to the present invention andthe powdered prescription drug enrofloxacin (5 mg/kg) to experimentalanimals.

FIG. 4 shows the plasma concentration of a powdered prescription drugwith time after administration of different formulations, eachcomprising a mixture of a gel-inducible composition for petadministration assistance according to the present invention and thedrug.

DETAILED DESCRIPTION

Hereinafter, the present invention will be described in detail.

The present invention provides a gel-inducible composition for petadministration assistance containing an oil component alone orcontaining a viscosity-adjusting agent in the oil component.

In a first embodiment, the gel-inducible composition for petadministration assistance contains an oil component alone. The oilcomponent includes a vegetable oil or an animal oil. As the vegetableoil, any one selected from the group consisting of canola oil, soybeanoil, corn oil, grapeseed oil and rice bran oil is preferably used.

In addition, as the animal oil, any animal oil may be used as long as itmaintains a liquid state at room temperature. Examples of animal oilsthat may be used in the present invention include, but are not limitedto, horse oil, squalene, lanolin, and the like.

In a second embodiment, the gel-inducible composition for petadministration assistance according to the present invention furthercontains a silicone-based or a biogum-based viscosity-adjusting agent inthe oil component which is preferably a vegetable oil.

The vegetable oil that is used in the gel-inducible composition for petadministration assistance according to the present invention may be anyone selected from the group consisting of canola oil, soybean oil, cornoil, grapeseed oil, and rice bran oil. The oil component may be selectedin consideration of compatibility and miscibility between the componentsof the composition.

In addition, the gel-inducible composition for pet administrationassistance according to the first or second embodiment of the presentinvention is designed to have a necessary viscosity such that, when apowdered drug is mixed with the composition, the mixture is completelyscooped up with a finger without flowing down and without leavingresidue in the container.

The preferred viscosity of the composition is 9,500 to 100,000 cP asmeasured using a rotational viscometer at a rotating speed of 10 rpm ata temperature of 25° C., and the composition having a viscosity withinthe above range is preferable because it may adhere to the ceiling ofthe pet's mouth. If the viscosity is lower than 9,500 cP, it isimpossible to completely scoop up the composition, due to theexcessively high flowability of the composition, making it difficult toadminister a prescription drug at an appropriate dosage. If theviscosity is higher than 100,000 cP, the composition will be excessivelydry and a prescription drug will not mix therewith, making it difficultto administer the drug.

FIG. 1 is a photograph showing a gel formulation in which a powdereddrug is added to the gel-inducible composition for pet administrationassistance according to the present invention. When the gel formulationis scooped up with a finger and applied to the ceiling of the pet'smouth, the gel formulation (mixture) may adhere to the ceiling of thepet's mouth without flowing down, and the drug may be naturally absorbedwhen the composition component melts. Thus, the gel formulation makes itpossible to administer a prescription drug at an appropriate dosage.

More preferably, the viscosity of the gel-inducible composition for petadministration assistance according to the second embodiment of thepresent invention is adjusted depending on the content of asilicone-based or biogum-based viscosity-adjusting agent in the oilcomponent. In an example of the present invention, sodiumsilicoaluminate used as the silicone-based viscosity-adjusting agent ispreferably contained in an amount of 20 to 45 parts by weight based on100 parts by weight of the vegetable oil. In this case, the viscositywithin the above-described range is satisfied. If the content of theviscosity-adjusting agent is out of the above-described range, thedesired viscosity may not be achieved. That is, it is impossible toachieve a viscosity at which a mixture of the composition and aprescription drug is completely scooped up with a finger without leavingresidue in the container.

In addition, when xanthan gum is used as the viscosity-adjusting agentin an example of the present invention, the desired viscosity issatisfied when xanthan gum is contained in an amount of 110 to 160 partsby weight based on 100 parts by weight of the vegetable oil.

An example of the present invention describes the use of canola oil, butis not limited thereto.

The silicone-based viscosity-adjusting agent is preferably sodiumsilicoaluminate containing Na₂O:Al₂O₃:SiO₂ at a molar ratio of 1:1:13.

The sodium silicoaluminate is a white fine amorphous powder or granule,and shows a loss in weight when dried at 105° C. for 2 hours. Here, theloss in weight should be less than 8.0 wt %. When the sodiumsilicoaluminate is quantitatively analyzed after dried at 105° C. for 2hours, it contains 6.0 to 76.0 wt % of silicon dioxide (SiO₂), 9.0 to13.0 wt % of aluminum oxide (Al₂O), and 4.0 to 7.0 wt % of sodium oxide(Na₂O).

In addition, the sodium silicoaluminate is dried at 150° C. for 2 hoursand then 5 g is weighed precisely and heated at 90° C. until theabove-described contents are reached, the loss in weight thereof shouldsatisfy the requirement of 8.0 to 13.0 wt %.

In addition, the biogum-based viscosity-adjusting agent used in thepresent invention may be any one selected from the group consisting ofxanthan gum, carrageenan, guar gum, diutan gum, cellulose gum, andgellan gum. Xanthan gum is used in an example of the present invention,but is not limited thereto.

The gel-inducible composition for pet administration assistanceaccording to the first or second embodiment of the present invention mayfurther contain a mixed enzyme preparation.

The enzyme is a protein that helps to obtain energy by hydrolyzing ahigh molecular organic compound of food into a low molecular organiccompound in the digestive tract of an animal. The enzyme that may becontained in the composition may be selected from the group consistingof protease, alpha-amylase, cellulase that is an enzyme degrading thedietary fiber cellulose, lipase, and pectinase that is an enzymedegrading the polysaccharide pectin.

In addition, when the composition according to the present inventioncontains mixed lactic acid bacteria together with the enzyme, it mayprovide a balance between in vivo degradation, and digestion and toxinrelease, in particular, and may be administered to, inter alia, dogs orcats with thin stools or diarrhea, cats or dogs in need of prevention ofenteritis, old dogs with weak intestines, or dogs or cats with reducedimmunity.

In addition, the composition according to the present invention maycontain chicken liver powder and conventional additives such as dextrosemonohydrate, an emulsifying agent and a preservative.

The chicken liver powder is an excellent source of protein, is rich invitamin A and vitamin B, especially vitamin B12, contains trace elementssuch as iron, copper, zinc, chromium, may be stored as spray-driedpowder for a long period of time, and is easy to use in all seasons.

The present invention also provides a packaged gel inducible product forpet administration assistance in which a powdered prescription drug iscontained in the gel-inducible composition for pet administrationassistance according to the first or second embodiment of the presentinvention in an amount of 5 to 10 wt % based on the standard daily foodintake of a pet.

Although the kind of powdered prescription drug is not particularlylimited, preferred examples of the powdered prescription drug includepowdered drugs for prevention or treatment of eye, joint, skin, liver,kidney, heart or dental diseases.

The drugs that are good for the eyes include lutein and astaxanthin, andthe drugs that are good for joints include green mussel and glucosamine.The drugs that are good for the skin include aloe, cysteine, andL-methionine, the drugs that are good for the liver include milkthistle, L-carnitine, and omega-3 fatty acids, and the drugs that aregood for kidneys include omega-3 fatty acids, vitamin B groups, andantioxidants. In addition, the drugs that are good for the heart includeL-carnitine, taurine, green tea extract (polyphenol), rosemary extract(polyphenol). Mutanase (plaque removing enzyme) and celery oil may beused as drugs for prevention of mouth ulcer and gum inflammation in dogsor cats.

At this time, the formulation of the packaging is not particularlylimited, but is preferably a paste gel formulation which may be providedas a disposable stick packaging, toothpaste packaging, or the like.

In addition, according to the present invention, the gel-induciblecomposition for pet administration assistance and a powderedprescription drug are introduced, and then mixed together to form a gel.The gel may be scooped up with a finger and attached to the ceiling ofthe pet's mouth, thereby administering the prescription drug at anappropriate dosage.

That is, when a prescription drug is powdered, the present invention mayprovide a gel-type formulation by predetermining the optimum viscosityof the gel-forming composition for facilitating pet drug administration,at which the composition is neither dry not flow down when mixed withthe drug, and mixing the composition with the drug by a simple mixingmeans.

FIG. 2 depicts photographs showing the dissolution behavior of a mixtureof the gel-inducible composition for pet administration assistanceaccording to the present invention and a powdered drug in an aqueousphase. As can be seen therein, the mixture does not dissolve at all inthe aqueous phase.

Thus, as the composition of the present invention contains the oilcomponent as a main component, a powdered drug mixed with thecomposition is completely coated with the oil component, so that it doesnot dissolve even in water. Thus, the composition of the presentinvention may provide a formulation that allows the powdered drug to besafely delivered to the intestine by blocking contact with gastric acidand absorbed in the intestine. Accordingly, the composition of thepresent invention may achieve a higher blood concentration of a drugthan when the drug is administered by other methods.

FIG. 3 shows the results of measuring AUC_(t) (n=4, mean+/−s.d.) amongin vivo pharmacokinetic parameters of enrofloxacin with time afteradministration of a mixture of the gel-inducible composition for petadministration assistance according to the present invention and thepowdered prescription drug enrofloxacin (5 mg/kg) to experimentalanimals.

Referring to FIG. 3, the antibiotic enrofloxacin powdered drug was mixedwith each of compositions prepared in Examples 2 and 11, and thenadministered to experimental animals (B and C in FIG. 3), and as aresult, it could be confirmed that the initial concentration of the drugin the blood was relatively high and the concentration was persistent,compared to those in a control group (A in FIG. 3) in which the drug wasmixed with sterile distilled water

Hereinafter, the present invention will be described in more detail withreference to examples. However, these examples are only to explain thepresent invention in more detail, and the scope of the present inventionis not limited thereto.

Example 1

Among the components shown in Table 1 below, components excluding sodiumsilicoaluminate were introduced into a container in the amounts shown inTable 1, and then mixed together at 20° C. for 60 minutes. Next, anaging step was performed, and the components were mixed while sodiumsilicoaluminate (loss in weight on drying: 6 wt %; average particlediameter: 8 μm; pH 10) was added slowly thereto, thereby preparing thecomposition of the present invention.

TABLE 1 Content (parts Component Content (wt %) by weight) Canola oil68.30 100 parts by weight Sodium silicoaluminate 13.64 20 parts byweight Sugar (dextrose monohydrate) 5.90 8.6 parts by weight Chickenliver powder 3.00 4.4 parts by weight Mixed enzyme preparation 2.10 3.1parts by weight Preservative 0.10 0.15 parts by weight Emulsifying agent0.10 0.15 parts by weight

Examples 2 to 4

Compositions were prepared in the same manner as in Example 1, exceptthat the content of sodium silicoaluminate based on 100 parts by weightof canola oil was changed as shown in Table 3 below.

Comparative Examples 1 and 2

Compositions were prepared in the same manner as in Example 1, exceptthat except that the content of sodium silicoaluminate based on 100parts by weight of canola oil was changed as shown in Table 3 below.

Examples 5 to 10

Compositions were prepared in the same manner as in Example 1, exceptthat xanthan gum as a viscosity-adjusting agent was used based on 100parts by weight of the vegetable oil component canola oil of thecomposition shown in Table 1 above and the content thereof was changedas shown in Table 4.

Comparative Examples 3 to 5

Compositions were prepared in the same manner as in Example 1, exceptthat the content of xanthan gum based on 100 parts by weight of canolaoil was changed as shown in Table 4 below.

Example 11

The components shown in Table 2 below were introduced into a containerin the amounts shown in Table 2, and then mixed together at 20° C. for60 minutes. Next, an aging step was performed, thereby preparing acomposition.

TABLE 2 Content (parts Component Content (wt %) by weight) Canola oil84.04 100 parts by weight Sugar (dextrose monohydrate) 5.90 14.2 partsby weight Chicken liver powder 3.00 28.0 parts by weight Preservative0.10 8.40 parts by weight Emulsifying agent 0.10 8.40 parts by weight

<Experimental Example 1> Viscosity Measurement

For the compositions prepared in the Examples and the ComparativeExamples, the viscosity of each composition was measured using arotational viscometer (BROOKFIELD (USA), Model: RVT).

A spindle was dipped in each composition to be measured so that it wasimmersed up to the marked portion. The spindle was immersed slightlyobliquely so that no bubbles were generated. Since it is general thatviscosity greatly changes depending on temperature, the viscosity wasmeasured under the following conditions after temperature stabilization.

After selecting the appropriate spindle and rotating speed (rpm),measurement was started by pressing the motor on/off key, and the valuewas recorded after waiting until a stable value was reached. Theoperation was stopped by pressing press the motor on/off key, and thesample was replaced. The conditions are as follows:

1) Spindle No.: No. RV/HA/HB-6

2) Rotating speed (rpm): 10

3) Sample temperature: 25° C.

The results are shown in Tables 3 and 4 below.

TABLE 3 Comparative Comparative Example 1 Example 2 Example 1 Example 2Example 3 Example 4 Canola oil 100 100 100 100 100 100 content (parts byweight) Sodium 5 10 20 30 40 45 silicoaluminate content (parts byweight) Viscosity (cP) 200 1,500 10,000 38,000 80,000 100,000

TABLE 4 Comparative Comparative Comparative Example Example ExampleExample Example Example Example 3 Example 4 Example 5 5 6 7 8 9 10Canola oil 100 100 100 100 100 100 100 100 100 content (parts by weight)Xanthan 80 90 100 110 120 130 140 150 160 gum content (parts by weight)Viscosity 2,500 4,500 6,100 9,700 12,900 16,500 22,500 74,000 108,000(cP)

From the results in Tables 3 and 4 above, based on the range thatsatisfies a viscosity of 9,500 to 100,000 cP (centipoise) as measuredusing the rotational viscometer at a rotating speed of 10 rpm at atemperature of 25° C., the kind and content of viscosity-adjusting agentin the vegetable oil were determined. Specifically, the compositions ofExamples 1 to 4 satisfied the desired viscosity when they containedsodium silicoaluminate in an amount of 20 to 45 parts by weight based on100 parts by weight of canola oil, and the compositions of Examples 5 to10 satisfied the desired viscosity when they contained xanthan gum in anamount of 110 to 160 parts by weight based on 100 parts by weight ofcanola oil.

It was confirmed that the composition having the viscosity within theabove-described viscosity range was completely scooped up with a fingerwithout leaving residue in the container and without flowing down.

<Experimental Example 2> Evaluation of Formulation Stability

Generally, when food enters the stomach, the food is crushed finely bygastric motility while it stays in the stomach for 2 hours (liquid food)or 4 hours (solid food). The crushed food is made like soft porridge bysecreted mucus, and gastric acid (pH=2 hydrochloric acid) is secreted inthe stomach and disinfects the food while the food stays in the stomachfor a long time.

For this reason, pharmaceutical drugs, particularly powdered drugs, havebeen administered to pets in mixtures with wet can feed, honey, jam,water, dry feed, liquid nutrients, snacks, etc. However, it remains aquestion whether the drug efficacy can be maintained when theseformulations and the powdered drugs are mixed and administered.

FIG. 2 depicts photographs showing the dissolution behavior of a mixtureof a gel-inducible composition for pet administration assistanceaccording to the present invention and a powdered drug in an aqueousphase.

FIG. 2(a) shows a commercially available liquid product for petnutrition containing vitamins and essential amino acids as activeingredients; FIG. 2(b) shows the composition of Example 2; FIG. 2(c)shows a commercially available product for a pet snack containing a tunaor chicken extract; and FIG. 2(d) shows a commercially available productfor a pet snack containing chicken breast and porcine liver.Specifically, FIGS. 2(a) to 2(d) show the results obtained by mixing thesame powdered drug with each of the products in water at 38° C. for 5minutes and allowing each mixture to stand for 5 minutes.

As a result, it was confirmed that the commercially available productspartially dissolved in water or were suspended as emulsions. From thisresult, it is expected that the powdered drug component may be exposedto gastric acid under mucus (moisture) conditions and may be destroyedto a considerable extent.

On the other hand, it was confirmed that the composition of Example 2did not dissolve at all in water.

From this result, it is expected that, as the composition of the presentinvention contains the oil component as a main component, a powdereddrug mixed with the composition will be completely coated with the oilcomponent, so that it will not dissolve even in water, and the drug willbe poorly soluble in the mucus (moisture) environment in the stomach,will be safely delivered to the intestine by blocking contact withgastric acid and absorbed in the intestine.

Accordingly, the composition of the present invention is a formulationthat may achieve a higher blood concentration of a drug than when thesame amount of the drug is administered by other methods.

<Experimental Example 3> Pharmacokinetic Analysis

For oral administration of enrofloxacin to a companion animal, such as adog or a cat, it is inevitable to prescribe enrofloxacin by crushing itinto powder and dispensing the powder, due to the low body weight of theanimal. However, a phenomenon frequently occurs in which the companionanimal refuses to take the drug during administration and the drug islost during this administration process. In addition, even if the drugis administered, the results of an experiment on how it affects theblood concentration and effect of the drug are significant.

As experimental animals, 9 male beagle dogs found to be clinicallyhealthy in physical examination were used in this clinical experiment.Animals with a history of receiving antibiotics in the last month werenot included in the experiment, and the experimental animals wererandomly divided into three groups, each consisting of 3 animals. Forexperimental groups, a powdered antibiotic (enrofloxacin, 5 mg/kg) wasmixed with each of the composition of Example 2 and the composition ofExample 11, and for a control group, the antibiotic was mixed withsterile distilled water in place of the composition. Each of themixtures was administered once orally to the experimental animals. 2.4ml of each mixture was administered to each animal regardless of thebody weight.

At each of 0, 15, 30, 45, 60, 90, 120, 180, 300, 420 and 960 minutesafter oral administration of the antibiotic and the test products, ablood samples was collected from the jugular veins, placed in a testtube (heparin tube) and centrifuged at 1500 rpm for 5 minutes. Theseparated plasma was transferred into an E-tube and stored frozen at−80° C. until analysis.

For measurement of the blood concentration of the antibiotic, thetime-dependent concentration of enrofloxacin in the plasma was measuredusing HPLC-MS/MS (API 4000 LC-MS/MS system) [Report on the Results ofResearch conducted by Kyungpook National University College ofVeterinary Medicine, April 2019].

Pharmacokinetic parameters were calculated using a model-independentanalysis method. The maximum plasma concentration (C_(max)) and the time(T_(max)) to reach the maximum plasma concentration were obtaineddirectly from the time-versus-plasma concentration curve of eachsubject. The elimination rate constant (k) was obtained by least squaresof the log-transformed plasma concentration of the elimination phase,and the half-life (t_(1/2)) was calculated from 0.693/k.

The area under the concentration-time curve (AUCt) was obtained by thetrapezoidal law, and the area under the concentration-time curveextrapolated to infinite time (AUC_(inf)) was obtained by adding thevalue obtained by dividing the final measured concentration by k. Thetotal clearance (Cl) was calculated by dividing AUC_(inf) by dosage.Pharmacokinetic parameters were expressed as the mean and standarddeviation of the data obtained from each subject.

The results are shown in Table 6 below and FIG. 3.

TABLE 5 Experimental group Composition A Enrofloxacin (Baytril) powder +sterile distilled water B Enrofloxacin (Baytril) powder + Example 2 CEnrofloxacin (Baytril) powder + Example 11

TABLE 6 Experimental Experimental Experimental Parameter group A group Bgroup C C_(max) (mg/L) 0.62 ± 0.15 1.24 ± 0.10 1.32 ± 0.04 T_(max) (h)0.75 ± 0.54 1.06 ± 0.31 0.67 ± 0.29 k (h⁻¹) 0.29 ± 0.02 0.30 ± 0.03 0.36± 0.02 t_(1/2) (h) 2.41 ± 0.19 2.31 ± 0.27 1.93 ± 0.12 AUC_(12 h) (mg ·h/L) 1 1.90 ± 0.67 4.48 ± 0.65 3.15 ± 0.76 AUC_(inf) (mg · h/L) 1.97 ±0.71 4.66 ± 0.74 3.20 ± 0.77 Cl (L/h/kg) 2.81 ± 1.02 1.10 ± 0.20 1.62 ±0.34

FIG. 3 shows the AUC results among in vivo pharmacokinetic parameters ofenrofloxacin with time after administration of a mixture of thegel-inducible composition for pet administration assistance according tothe present invention and the powdered prescription drug enrofloxacin (5mg/kg) to experimental animals.

As a result, when the enrofloxacin powder drug was mixed with thecomposition of Example 2 and administered to the dogs, the degree ofabsorption of the drug significantly increased (p<0.005) compared towhen the drug was administered as a mixture with the control (drinkingwater).

In addition, the enrofloxacin powder drug was mixed with the compositionof Example 11 and administered to the dogs, the plasma concentration ofenrofloxacin tended to increase, but statistical significance was notshown due to large variation between the subjects.

From the above results, it could be confirmed that, when the drug wasadministered as a mixture with the gel-inducible composition for petadministration assistance according to the present invention, the plasmaconcentration and degree of absorption of the drug increased compared towhen the drug was administered as a mixture with drinking water.

Thus, the composition of Example 2 or 11 may serve as an administrationaid, which does not reduce the efficacy of a powdered drug, for aguardian who has difficulty administering a powdered drug.

In particular, it could be confirmed that Example 2 further containingthe mixed enzyme preparation in the composition of Example 11 andExample 2 containing canola oil enhanced the absorption ability of thedrug component.

<Experimental Example 4> Change in Drug Concentration BetweenFormulations

A gel inducible product packaged in a stick pack was prepared by mixingthe antibiotic enrofloxacin powder drug with the composition prepared inExample 2. The gel inducible product contained 5 mg of enrofloxacin perkg body weight of a dog.

As another test group, a pill formulation of enrofloxacin was mixed withthe composition prepared in Example 2, and as a control group, theenrofloxacin powder drug was contained in sterile distilled water. Eachof the formulations was administered orally to dogs.

During 12 hours (0, 5, 10, 15, 30, 45, 60, 90, 120, 180, 300, 420 and720 minutes) after drug administration, blood samples were collected,and the plasma concentration of enrofloxacin in each blood sample wasanalyzed using HPLC-MS/MS (API 4000 LC-MS/MS system).

The results of the analysis are shown in Table 7 below and FIG. 4.

TABLE 7 Time-dependent changes in concentration (μ/ml) of enrofloxacinin dog plasma Time (min) Control group Test group A Test group B afterdrug Water + Example 2 + Example 2 + administration powdered drugpowdered drug pill 0 0 0 0 5 49 57 0 10 721 63 712 15 772 157 996 30 706711 1154 45 723 943 1155 60 708 1137 1046 90 502 1214 979 120 398 1011702 180 288 708 452 300 155 316 242 420 86 195 102 720 29 47 31

FIG. 4 shows the plasma concentration of the powdered prescription drugwith time after administration of different formulations, eachcomprising a mixture of the gel-inducible composition for petadministration assistance according to the present invention and thedrug. From the above results, it can be seen that test group A obtainedby mixing the powdered drug with the composition prepared in Example 2exhibited a significantly high initial plasma concentration of the drugcomponent.

As described above, the gel-inducible composition for pet administrationassistance according to the present invention may exhibit a viscositysufficient to adhere to the ceiling of the pet's mouth by containing anoil component alone or containing a high concentration of aviscosity-adjusting agent in the oil component.

In addition, the gel-inducible composition for pet administrationassistance according to the present invention may further contain apowdered prescription drug, and when the composition is scooped up witha finger and applied to the ceiling of the pet's mouth, the mixture ofthe composition and the prescription drug may completely adhere to theceiling of the pet's mouth without flowing down, and the drug may benaturally absorbed when the composition melts. Thus, the compositionmakes it possible to administer the prescription drug at an appropriatedosage.

Therefore, the gel-inducible composition for pet administrationassistance according to the present invention may increase digestion andabsorption by adding a taste that a pet likes or by adding an enzyme,and may be provided as a pet-specific formulation having a desiredviscosity by simple mixing with a dosage of a powdered drug prepared ina veterinary hospital.

Although the present invention has been described in detail only withrespect to the described embodiments, it is apparent to those skilled inthe art that various changes and modifications are possible withoutdeparting from the technical spirit and scope of the present invention,and these changes and modifications fall within the scope of theappended claims.

1. A gel-inducible composition being capable of pet administration witha powdered prescription drug, the gel-inducible composition comprising:an oil component including a vegetable oil, the vegetable oil includingat least one selected from the group consisting of canola oil, soybeanoil, corn oil, grapeseed oil, and rice bran oil; a silicone-basedviscosity-adjusting agent or a biogum-based viscosity-adjusting agent,wherein the silicone-base viscosity-adjusting agent is sodiumsilicoaluminate contained in 20 to 45 parts by weight based on 100 partsby weight of the oil component, and the biogum-based viscosity-adjustingagent is xanthan gum contained in 110 to 160 parts by weight based on100 parts by weight of the oil component; and a viscosity of 9,500 to100,000 cP as measured using a rotational viscometer at a rotating speedof 10 rpm at a temperature of 25° C., wherein the powdered prescriptiondrug includes lutein, astaxanthin, green mussel, glucosamine, aloe,cysteine, L-methionine, milk thistle, L-carnitine, omega-3 fatty acids,vitamin B groups, antioxidants, taurine, green tea extract (polyphenol),rosemary extract (polyphenol), mutanase (plaque removing enzyme), andcelery oil.
 2. (canceled)
 3. The gel-inducible composition of claim 1,further comprising: an enzyme.
 4. The gel-inducible composition of claim3, wherein the enzyme is at least one selected from the group consistingof protease, alpha-amylase, cellulase degrading dietary fiber cellulose,lipase, and pectinase degrading polysaccharide pectin. 5.-9. (canceled)10. A packaged gel inducible product being capable of petadministration, the packed gel inducible product comprising: the gelinducible composition of claim 1; and the powdered prescription drug inan amount of 5 to 10 wt % based on a standard daily food intake per bodyweight of a pet.
 11. The packaged gel inducible product claim 10,wherein the gel inducible product is insoluble in an aqueous phase andis soluble in an oil phase.
 12. The gel-inducible composition of claim10, further comprising: an enzyme.
 13. The gel-inducible composition ofclaim 12, wherein the enzyme is at least one selected from the groupconsisting of protease, alpha-amylase, cellulase degrading dietary fibercellulose, lipase, and pectinase degrading polysaccharide pectin.14.-18. (canceled)